Progress in active-specific immunotherapy of brain malignancies (Q34075068)

30 July 2017

1 reference

title

Progress in active-specific immunotherapy of brain malignancies (English)

1 reference

30 July 2017

1 reference

Tjoa BA

1

1 reference

30 July 2017

Salgaller ML

series ordinal

2

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 September 2000

1 reference

Expert Opinion on Investigational Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

9

1 reference

30 July 2017

issue

9

1 reference

30 July 2017

page(s)

2093-2101

1 reference

30 July 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

The basis for current treatment recommendations for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Development and implementation of intraoperative magnetic resonance imaging and its neurosurgical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Immune defects observed in patients with primary malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Modulation of proliferation and antigen expression of a cloned human glioblastoma by interleukin-4 alone and in combination with tumor necrosis factor-alpha and/or interferon-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Tumour necrosis factor-alpha induces an increase in susceptibility of human glioblastoma U87-MG cells to natural killer cell-mediated lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Addition of IFN-alpha to treatment of malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Clinical effect of intra-arterial tumor necrosis factor-alpha for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Systemic T cell adoptive immunotherapy of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Interleukin-12-based immunotherapy against rat 9L glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Antigen-presenting cell types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Antigen processing for amateurs and professionals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

The dendritic cell system and its role in immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Dendritic cells as antigen presenting cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

The distinct surface of human blood dendritic cells, as observed after an improved isolation method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.9.2093

10.1517/13543784.9.9.2093

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference